{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:09:24Z","timestamp":1779894564220,"version":"3.53.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":448,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jtct.2021.12.005","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T04:28:09Z","timestamp":1640233689000},"page":"145-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed\/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7029-1769","authenticated-orcid":false,"given":"Olivier","family":"Veilleux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Claveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habiba","family":"Alaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmina","family":"Serroukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Delisle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia M.","family":"Bambace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Sauvageau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigina","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis-Claude","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lachance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.12.005_bib0001","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0002","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0003","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.12.005_bib0004","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PPO.0000000000000330","article-title":"Treatment-resistant Hodgkin lymphoma: defining the role of autologous transplantation","volume":"24","author":"Blum","year":"2018","journal-title":"Cancer J"},{"key":"10.1016\/j.jtct.2021.12.005_bib0006","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2021.12.005_bib0007","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2021.12.005_bib0008","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/ejh.13186","article-title":"Allogeneic hematopoietic stem cell transplantation in r\/r Hodgkin lymphoma after treatment with checkpoint inhibitors: feasibility and safety","volume":"102","author":"Dada","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0009","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/asheducation-2018.1.213","article-title":"Where does PD-1 blockade fit in HL therapy?","volume":"2018","author":"Herrera","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2021.12.005_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2014.04.003","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis","volume":"92","author":"Rancea","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0011","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.005_bib0012","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.hemonc.2017.05.010","article-title":"High dose chemotherapy and autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: emerging questions, newer agents, and changing paradigm","volume":"10","author":"Akhtar","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jtct.2021.12.005_bib0013","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2141.2003.04828.x","article-title":"Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease","volume":"124","author":"Moskowitz","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0014","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.005_bib0015","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdn052","article-title":"Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0016","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/asheducation-2016.1.331","article-title":"Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma","volume":"2016","author":"Moskowitz","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.jtct.2021.12.005_bib0017","doi-asserted-by":"crossref","first-page":"iv25","DOI":"10.1093\/annonc\/mdj995","article-title":"Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma","volume":"17 suppl 4","author":"Hertzberg","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0018","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","article-title":"Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Baetz","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0019","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study","volume":"34","author":"Santoro","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0020","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0021","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood.V128.22.1834.1834","article-title":"Safety and activity of brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed\/refractory (Rel\/Ref) classical Hodgkin lymphoma (cHL): initial results of a phase I\/II trial","volume":"128","author":"Cassaday","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.005_bib0022","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study","volume":"106","author":"Kersten","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.12.005_bib0023","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.005_bib0024","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.005_bib0025","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","article-title":"Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma","volume":"146","author":"Moskowitz","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0026","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ajh.24792","article-title":"Outcomes of patients with relapsed\/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis","volume":"92","author":"Bair","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0027","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2021.12.005_bib0028","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.12.005_bib0029","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1008362700606","article-title":"Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study","volume":"11","author":"Shamash","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0030","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.V80.8.2142.2142","article-title":"Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up","volume":"80","author":"Vose","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.005_bib0031","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bmt.1704214","article-title":"Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma","volume":"32","author":"Kewalramani","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.005_bib0032","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"28","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0033","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41409-019-0640-z","article-title":"Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment","volume":"55","author":"Rivas","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.005_bib0034","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.15152","article-title":"Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party","volume":"181","author":"Bazarbachi","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0035","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00277-019-03662-6","article-title":"Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients","volume":"98","author":"Gaudio","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0036","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.005_bib0037","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0038","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.3324\/haematol.2019.215962","article-title":"PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed\/refractory Hodgkin lymphoma patients: a retrospective single center case series","volume":"104","author":"Casadei","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.12.005_bib0039","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2013-05-500801","article-title":"Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality","volume":"122","author":"Saha","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.005_bib0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.005_bib0041","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/bloodadvances.2019001336","article-title":"Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma","volume":"4","author":"De Philippis","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.12.005_bib0042","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.005_bib0043","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.bbmt.2018.07.025","article-title":"Haploidentical transplants with post-transplant cyclophosphamide for relapsed or refractory Hodgkin lymphoma: the role of comorbidity index and pretransplant positron emission tomography","volume":"24","author":"Marani","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.005_bib0044","doi-asserted-by":"crossref","first-page":"xi22","DOI":"10.1093\/annonc\/mdz449.016","article-title":"Safety and efficacy of allogeneic stem cell transplantation after nivolumab therapy for patients with relapsed\/refractory classical Hodgkin lymphoma","volume":"30","author":"Beynarovich","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2021.12.005_bib0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.005_bib0046","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood-2014-11-608406","article-title":"Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation","volume":"125","author":"Roberto","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.005_bib0047","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.005_bib0048","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.12.005_bib0049","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721014378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721014378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:01:47Z","timestamp":1763002907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721014378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2666636721014378"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.12.005","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed\/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}